|
|
Article: Insmed Begins Phase III Study Of Hormone Therapy For GHIS.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
With near-term plans mapped out for approval of its lead product, Insmed Inc. began a pivotal Phase III trial of its late-stage hormone replacement therapy in children with growth hormone insensitivity syndrome (GHIS).
The study is designed to measure rhIGF-I/rhIGFBP-3's effect on an increase in height velocity in patients with the genetic disorder, which causes them to fail to produce insulin-like growth factor-I (IGF-I). The product combines IGF-I, a protein integral to the actions of both insulin and growth hormone, with a secondary protein called binding protein-3 (BP-3), to which IGF-I binds and circulates throughout the human body in ...